Skip to main content
Premium Trial:

Request an Annual Quote

Imagene Labs, Kalbe Partner for Genetic Risk Tests

NEW YORK – Indonesian healthcare provider Kalbe and Singaporean genome analysis firm Imagene Labs said last Friday that they have partnered to develop genetic risk tests.

Kalbe is launching two new DNA tests that employ patented ancestry-based genetic risk scoring technology developed by Imagene Labs. The PrimeGenme test analyzes more than 1,800 genetic variants related to longevity and healthy aging, while the KiddyGenme test looks at more than 300 genes to provide “insights into a child’s innate talents and personality,” the companies said.

The tests will be commercially available to consumers through Kalbe’s e-commerce site and its network of hospital and clinic partners, according to the firms.

Last year, Imagene Labs struck a partnership with Invenio Genetics in California to develop an improved fitness and nutrition consumer genomics test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.